Tucker Douglass W, Gogia Angad S, Donoho Daniel A, Yim Benjamin, Yu Cheng, Fredrickson Vance L, Chang Eric L, Freidman Rick A, Zada Gabriel, Giannotta Steven L
Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
World Neurosurg. 2019 Feb;122:366-371. doi: 10.1016/j.wneu.2018.11.009. Epub 2018 Nov 15.
Acoustic neuromas (ANs) are benign intracranial tumors that arise from myelin-forming Schwann cells surrounding the vestibular branch of the vestibulocochlear nerve (cranial nerve VIII). Treatment options for AN include observation, radiosurgery, and microsurgical resection. Gamma Knife radiosurgery (GKRS) for AN has well-documented short-term safety and efficacy for carefully selected patients. Recent innovations in GKRS technology may improve long-term outcomes. The aim of this study was to report long-term tumor control and complication rates after GKRS for sporadic AN.
A retrospective review was performed of patients with sporadic ANs at Keck Hospital of USC who underwent GKRS from 1995 to 2015 with a minimum follow-up of 12 months.
Median age at treatment was 63.7 years (range, 19.4-84.2 years). Median follow-up time was 69 months. Median tumor diameter was 17.5 mm (range, 5.0-29.0 mm), and median treatment volume was 2.41 cm (range, 0.09-12.8 cm). Median prescribed dose was 12.50 Gy. Tumor control was achieved in 51 (98.1%) patients over the follow-up period (12-192 months). One patient experienced tumor progression at 22 months after GKRS, requiring surgical intervention, which ultimately resulted in remission. Complications included hearing loss (17.3%), worsened balance/ataxia (7.7%), and hydrocephalus (1.92%).
Patients undergoing GKRS for sporadic ANs had high rates of tumor control over a median follow-up time of >5 years. Improvements in radiosurgery treatment planning were seen in the most recent cohort of patients. GKRS is a safe and effective modality for treating sporadic ANs in selected patients.
听神经瘤(ANs)是起源于前庭蜗神经(第八对脑神经)前庭支周围形成髓鞘的施万细胞的良性颅内肿瘤。听神经瘤的治疗选择包括观察、放射外科手术和显微手术切除。对于精心挑选的患者,伽玛刀放射外科手术(GKRS)治疗听神经瘤具有充分记录的短期安全性和有效性。GKRS技术的最新创新可能会改善长期疗效。本研究的目的是报告散发性听神经瘤GKRS治疗后的长期肿瘤控制情况和并发症发生率。
对1995年至2015年在南加州大学凯克医院接受GKRS治疗且随访至少12个月的散发性听神经瘤患者进行回顾性研究。
治疗时的中位年龄为63.7岁(范围19.4 - 84.2岁)。中位随访时间为69个月。中位肿瘤直径为17.5毫米(范围5.0 - 29.0毫米),中位治疗体积为2.41立方厘米(范围0.09 - 12.8立方厘米)。中位处方剂量为12.50 Gy。在随访期(12 - 192个月)内,51例(98.1%)患者实现了肿瘤控制。1例患者在GKRS术后22个月出现肿瘤进展,需要手术干预,最终缓解。并发症包括听力丧失(17.3%)、平衡/共济失调加重(7.7%)和脑积水(1.92%)。
接受GKRS治疗散发性听神经瘤的患者在中位随访时间超过5年时肿瘤控制率较高。在最近一组患者中,放射外科治疗计划有所改进。GKRS是治疗特定患者散发性听神经瘤的一种安全有效的方法。